Photocleavable Linker for Protein Affinity Labeling to Identify the Binding Target of KCN-1 by Tran, Hang T
Georgia State University
ScholarWorks @ Georgia State University
Chemistry Theses Department of Chemistry
Summer 8-1-2010
Photocleavable Linker for Protein Affinity Labeling
to Identify the Binding Target of KCN-1
Hang T. Tran
Georgia State University, htran14@student.gsu.edu
Follow this and additional works at: https://scholarworks.gsu.edu/chemistry_theses
This Thesis is brought to you for free and open access by the Department of Chemistry at ScholarWorks @ Georgia State University. It has been
accepted for inclusion in Chemistry Theses by an authorized administrator of ScholarWorks @ Georgia State University. For more information, please
contact scholarworks@gsu.edu.
Recommended Citation
Tran, Hang T., "Photocleavable Linker for Protein Affinity Labeling to Identify the Binding Target of KCN-1." Thesis, Georgia State
University, 2010.
https://scholarworks.gsu.edu/chemistry_theses/35
 PHOTOCLEAVABLE LINKER FOR PROTEIN AFFINITY LABELING TO IDENTIFY THE 
BINDING TARGET OF KCN-1 
 
 
by 
 
 
HANG T. TRAN 
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ABSTRACT 
 
 
KCN-1 is known to reduce tumor growth 6-fold in mice implanted with LN229 glioma 
cells.  Although this inhibitor is effective, the mechanism of action for KCN-1 is not well 
understood.  Based on preliminary studies, KCN-1 reduces tumor growth by disrupting the 
HIF-1 (hypoxia-induced factor-1) pathway.  The binding target of KCN-1 needs to be 
investigated in order to develop KCN-1 or its analogs for therapeutic applications.  In this 
research, a molecule was designed and synthesized for the identification of the binding target of 
KCN-1.  Specifically, this molecule contains the inhibitor (KCN-1), a photocleavable linker, 
 beads, and the affinity label (L-DOPA).  When UV light shines on the linker, the trans-alkene 
isomerizes to cis-alkene and undergoes intramolecular ring-closing reaction, which helps cleave 
the immobilized bead from the linker.  The immobilized bead is used to separate the binding 
fragment attached to the photocleavable linker from the solution after enzyme digestion.  The 
affinity label (L-DOPA) reacts with a nucleophile from the binding target and creates a covalent 
bond.  If the design is successful, this method is able to analyze the mass of the peptide sequence 
and determine the binding target of KCN-1. 
INDEX WORDS: Photocleavable linker, Affinity label, KCN-1, HIF-1 pathway 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 PHOTOCLEAVABLE LINKER FOR PROTEIN AFFINITY LABELING TO IDENTIFY THE 
BINDING TARGET OF KCN-1 
 
 
 
 
by 
 
 
 
 
HANG T. TRAN 
 
 
 
 
A Thesis Submitted by Partial Fulfillment of the Requirements for the Degree of 
Master of Science 
in the College of Arts and Sciences 
Georgia State University 
2010 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright by 
Hang T. Tran 
2010 
 
 
 PHOTOCLEAVABLE LINKER FOR PROTEIN AFFINITY LABELING TO IDENTIFY THE 
BINDING TARGET OF KCN-1 
 
 
by 
 
 
HANG T. TRAN 
 
 
Committee Chair: Dr. Binghe Wang  
 
Committee: Dr. George Y. Zheng  
Dr. Stuart Allison  
 
 
 
 
Electronic Version Approved: 
 
Office of Graduate Studies 
College of Arts and Sciences 
Georgia State University 
iv 
ACKNOWLEDGEMENTS 
 
I would like to thank my research advisor Dr. Binghe Wang for his guidance and for 
showing me that success comes from dedication and perseverance.  I would also like to thank the 
members of Dr. Wang’s Research Group for their help throughout my research career.  I 
especially want to thank Weixuan Chen, my mentor, for his persistence and patience while 
guiding me through my research project. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
v 
TABLE OF CONTENTS 
 
ACKNOWLEDGEMENTS ...............................................................................................................iv 
LIST OF SCHEMES..........................................................................................................................vi 
LIST OF FIGURES ...........................................................................................................................vii 
CHAPTERS 
 1. INTRODUCTION 
  1.1 Hypoxia ..........................................................................................................1 
  1.2 HIF-1 Pathway ...............................................................................................1 
  1.3 KCN-1 Inhibitor .............................................................................................3 
  1.4 Affinity Labeling ...........................................................................................4 
  1.5 Purpose of the Study ......................................................................................6 
 2. DISCUSSION/RESULTS 
  2.1 Synthesis of Compound 11 ............................................................................10 
  2.2 Synthesis of KCN-1 amine 12d .....................................................................12 
  2.3 Approaches to Compound 13 .........................................................................13 
 3. CONCLUSIONS .......................................................................................................16 
 4. EXPERIMENT 
  4.1 General Methods ............................................................................................17 
  4.2 Photocleavable Linker ...................................................................................17 
  4.3 KCN-1 amine .................................................................................................23 
REFERENCES ..................................................................................................................................25 
APPENDICES ...................................................................................................................................27 
vi 
LIST OF SCHEMES 
 
Scheme 1.  Synthetic route of compound 11 .....................................................................................10 
Scheme 2.  Synthetic route of compound 12d (KCN-1 amine). ........................................................12 
Scheme 3.  Synthetic routes of final deprotected compound 13b. .....................................................13 
Scheme 4.  Test model reactions of boron trihalides in DCM under -100oC ....................................14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vii 
LIST OF FIGURES 
 
Figure 1.1:  A comparison of hypoxia-inducible factor-1 pathway in ...............................................2 
normoxia and hypoxia 
Figure 1.2:  Molecular structure of KCN-1. ......................................................................................3 
Figure 1.3:  Kodadek laboratory’s novel type chemically activated molecule used to .....................5 
determine the binding target of free ubiquitin. 
Figure 1.4:  Photocleavable linker attached to the immobilized bead, ..............................................6 
LDOPA, and KCN-1 
Figure 1.5:  Proposed mechanism of the affinity label, LDOPA, to covalently. ...............................7 
link to the target protein. 
Figure 1.6:  Proposed mechanism of the photocleavable linker. .......................................................8 
Figure 1.7:  The retrosynthetic analysis of the photocleavable linker ...............................................9 
Figure 2.1:  Test model reactions monitored by TLC ........................................................................15 
 
 
 
 
1 
1. INTRODUCTION 
1.1 Hypoxia 
Hypoxia is a condition of oxygen deprivation.  When oxygen level decreases, an adaptive 
response occurs that is mediated by hypoxia-inducible factor-1 (HIF-1)1.  HIF-1 activates 
transcription of genes that help cells survive in low oxygen conditions.  These genes code for 
proteins that promote angiogenesis to form new blood vessels, glucose metabolism to provide 
more energy, and cell proliferation. 
Hypoxia commonly occurs in solid tumors because oxygen is limited in the interior of the 
tumor mass2.  The blood vessel is too far from the hypoxic area to deliver adequate amount of 
oxygen.  Thus, there is an increase of HIF-1 activity and stabilization in those areas.  As a result, 
the activation of genes helps solid tumor cells survive and expand.  Hypoxia is a major driving 
force of tumor progression because cells undergo adaptive genetic changes that prevent hypoxia-
induced cell death and necrosis2. 
1.2 HIF-1 Pathway 
Hypoxia-inducible factor-1 (HIF-1) is a transcription factor that responds to changes in 
oxygen and is up-regulated in hypoxia3.  It is a heterodimeric protein that consists of HIF-1α and 
HIF-1β subunits.  HIF-1α is oxygen-sensitive consisting of an oxygen-dependent degradation 
(ODD) domain.  HIF-1β completes the heterodimeric protein and binds with HIF-1α for the 
translocation to the nucleus. 
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Figure 1.1:  A comparison of hypoxia-inducible factor-1 pathway in normoxia and 
hypoxia4 
 
Under normoxia, as shown in Figure 1.1, HIF-1α subunit has an exceptionally short 
half-life because it is subjected to rapid turnover and degradation by the ubiquitin proteasome 
pathway5.  Since oxygen is available, the oxygen-dependent degradation (ODD) domain 
undergoes hydroxylation by prolyl hydoxylases (PHDs) and factor inhibiting HIF-1 (FIH-1).  
The PHDs and FIH-1 are iron-dependent enzymes requiring oxygen to hydroxylate prolines and 
asparagines, respectively, in the ODD domain.  As a result of the hydroxylated prolines, the von 
Hippel-Lindau protein (VHL) binds to the HIF-1α subunit, which leads to ubiquitination.  Since 
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the asparagines are hydroxylated, the transcription co-activator (CBP/p300) cannot bind to the 
HIF-1α subunit, which leads to transcriptional repression.  Thus, transcriptional activity is 
reduced and HIF-1α subunit undergoes proteasomal degradation.   
Under hypoxic condition, as shown in Figure 1.1, HIF-1α subunit cannot be hydroxylated 
because of decreased oxygen availability.  This means that VHL cannot bind to HIF-1α subunit 
and cannot lead to proteosomal degradation.  HIF-1α subunit is abundant and binds to the 
transcription co-activator (CBP/p300), which initiates the transcriptional activity.  Then, HIF-1β 
subunit binds to the HIF-1α subunit and the heterodimeric protein translocates to the nucleus for 
the transcription of genes.  These genes include erythropoiesis (Epo) to produce red blood cells, 
vascular endothelial growth factor A (VEGF) to form more blood vessels, and glucose 
metabolism (Glut1) to provide energy for cells5. 
1.3 KCN-1 Inhibitor 
HIF-1 is overly expressed in human cancer.  Since more genes are expressed, as well as 
altered, many tumors undergo genetic changes that facilitate adaptation and survival of the cells2.  
Thus, these adaptations and genetic changes make tumor cells more resistance to conventional 
treatments, such as chemotherapy2.  Therefore, inhibition of HIF-1 leads to anti-tumor effects 
and can be a target for drug development. 
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Figure 1.2:  Molecular structure of KCN-1. 
 
The interest of finding small molecules that disrupt the HIF-1 pathway led to an inhibitor 
known as KCN-1.  KCN-1, shown in Figure 1.2,  is a lead compound identified by screening a 
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10,000 member combinatorial library from Nicolaou6.  It was chosen for evaluation in Dr. Van 
Meir’s laboratory at Emory University. Preliminary in vivo experiments of KCN-1 showed 
significant anti-tumor activity.  Nude mice were implanted with LN229 glioma tumor cells on 
both hind flanks.  After one week, one group of mice was injected with KCN-1 (60 mg/kg; 5 
days/week) and the vehicle.  The other group received the vehicle alone, the control.  The mice 
injected with KCN-1 showed 6-fold less in tumor mass than the control.  Based on the results, 
KCN-1 reduces and slows tumor growth.  In addition, the KCN-1 injected mice displayed no 
apparent signs of toxicity or other negative effects.   
Although KCN-1 is a potent inhibitor that reduces tumor growth dramatically, the 
binding target of KCN-1 is not known.  However, there is evidence to support that KCN-1 binds 
to component of the HIF-1 pathway.  Based on other preliminary studies done in collaboration 
with the Van Meir lab, KCN-1 may bind to transcription co-activator p300.  This study was 
performed by Oregon Green fluorophore modified KCN-1 for cell imaging.  Although results 
showed that KCN-1 binds to transcription co-activator p300, further experiments are needed to 
confirm this mechanism of KCN-1 interacting in tumor cells.  Therefore, protein affinity labeling 
experiments will be used to identify the binding target of KCN-1. 
1.4 Affinity Labeling 
There are many techniques for tagging proteins.  One of these techniques is affinity 
labeling.  This method uses the property of recognition between two different molecules to react 
and form a chemical bond.  It is widely used to identify proteins, localize binding sites, and 
determine targets of drugs.  The affinity label molecule binds specifically and reversibly to the 
target protein7.  However, when it is photo-activated or chemically activated, it forms a highly 
reactive intermediate and reacts irreversibly with the nucleophilic residue of the target protein7.   
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Figure 1.3:  Kodadek laboratory’s novel type chemically activated molecule used to 
determine the binding target of free ubiquitin8 
 
In recent years, the Kodadek laboratory developed a novel type of chemically activated 
molecule that formed an extremely reactive electrophilic intermediate.  This method was used to 
determine the binding target of free ubiquitin (Ub).  The molecule contained ubiquitin tagged 
with a biarsenical fluorescein derivative (F1AsH), a biotin moiety, and a catechol of the 
dihydroxyphenylalanine (L-DOPA)8.  The most important aspect of this molecule was the 
catechol of L-DOPA as shown in Figure 1.3.  The catechol ring of the L-DOPA subunit can be 
oxidized to an ortho-quinone selectively with sodium periodate (NaIO4)8.  At close proximity 
between the ubiquitin and its binding target protein, the electrophilic quinone intermediate reacts 
with the nucleophilic residue of the protein8.  The results showed that the proteasome function 
was not affected by the chemical activator NaIO4.  Since the Kodadek method was very effective 
in their studies, it will be used for the affinity labeling work in this research.  The affinity label 
(L-DOPA) will be utilized to investigate the binding of KCN-1 to its target protein. 
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1.5 Purpose of the Study 
 
Figure 1.4:  Photocleavable linker attached to the immobilized bead, L-DOPA, and 
KCN-1. 
 
The purpose of this study is to design a small molecule that will identify the binding 
target of KCN-1.  Thus, the objective is to synthesize the molecule shown in Figure 1.4.  This 
molecule contains inhibitor KCN-1, a chemically activatable affinity label L-DOPA, the bead, 
and a photocleavable linker. 
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Figure 1.5:  Proposed mechanism for the affinity label, L-DOPA, to covalently link to the 
target protein.  
 
The proposed mechanism of this project consists of KCN-1 binding to a protein at a 
specific site.  As mentioned above, the L-DOPA is the chemically activatable affinity label 
molecule.  It is used to form a covalent bond with the binding target.  When the target protein 
and the KCN-1 are closely associated, the chemical activator NaIO4 converts the catechol of L-
DOPA to a very reactive electrophile.  As shown in Figure 1.5, sodium periodate (NaIO4) 
oxidizes the catechol of L-DOPA to form 1,2-benzoquinone9.  Thus, a nucleophile from the 
receptor of the target protein reacts with this electrophilic quinone.  This reaction converts the 
quinone back to the catechol9.  Overall, this procedure forms a covalent bond between the 
affinity label molecule L-DOPA and the binding target.   
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Figure 1.6:  Proposed mechanism of the photocleavable linker. 
 
After the protein undergoes enzyme digestion, as shown in Figure 1.6, the fragment 
covalently bound to the photocleavable linker is pulled out through the use of the bead, which is 
insoluble so it can easily separate from the solution and other fragments.  The linker and 
immobilized bead are cleaved from the rest of the molecule once separated from the solution.  
This process occurs when UV light of 365 nm excites the trans-alkene, leading to isomerization 
and formation of the cis-alkene10.  The linker then undergoes intramolecular cyclization reaction.  
The carbonyl, adjacent to the double bond carbon, reacts with the hydroxyl, on the aromatic ring, 
to form a chromanone and cleaves the KCN-1, L-DOPA, and the residue covalently bond to the 
L-DOPA10.  Then, the covalently linked residue is analyzed through mass spectroscopy by ESI or 
MALDI.  The molecular weight is used to determine the sequence of the binding target.  If the 
design is successful, this method is able to analyze the mass of the binding sequence and identify 
the target protein. 
9 
Figure 1.7:  The retrosynthetic analysis of the photocleavable linker. 
 
The retrosynthesis of the photocleavable linker is shown in Figure 1.7.  Amidation is the 
key component, which makes this synthetic route possible.  Deprotection of Boc- and MOM- 
group make it possible for the amidation with the immobilized bead.  Compound 11 is formed by 
reacting KCN-1 free amine 12d and carboxylic acid of the L-DOPA 10.  The L-DOPA fragment 
is commercially available and is added by yet another amidation with the linker 8. 
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2. DISCUSSION 
2.1 Synthesis of Compound 11 
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Scheme 1.  Synthetic route of compound 11 
 
The synthesis of the photocleavable linker was accomplished in 3.6% overall yield, as 
shown in Scheme 1.  The first step was the iodination of commercially available 
m-hydroxybenzoic acid 1 by the use of iodine and potassium iodide in aqueous ammonia.  The 
11 
aromatic carboxylic acid 2 was reduced with borane in tetrahydrofuran to generate primary alkyl 
benzylic alcohol 3.  Protection of the hydroxyl was needed for the conversion of the alcohol 4 to 
azide 5.  Thus, the hydroxyl on the aromatic ring 3 was protected with chloromethyl methyl ether 
(MOMCl).  The next step was azidation of the primary alkyl benzylic alcohol 4 using 
diphenylphosphoryl azide (DPPA) in the presence of strong organic base diazabicycloundecane 
(DBU).  This reaction was preceded by O-phosphorylation followed by SN2 displacement to 
generate the azide compound 5.  This compound was reduced to amine by a mild method of 
Staudinger reaction, which used triphenylphosphine as the reducing agent11.  The final reaction 
yielded triphenylphosphine oxide as the side product and the amine compound 6.  The amine 
needed to be preserved for the attachment with the bead at the end.  Thus, the Boc-protected 
compound 7 was generated using di-tert-butyl dicarbonate in the presence of base triethylamine 
in methanol.  The next step was to create the photochemical esterase.  This step was a simple 
Heck reaction using palladium catalyze carbon-carbon coupling between aryl iodide and 
activated alkene, acrylic acid, in the presence of K2CO3 base12.  The carboxylic acid 8 was 
activated with N-hydroxysuccinimide (NHS) and coupling reagent 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide) (EDCI) in dichloromethane (DCM).  The activated ester 9 
reacted with commercially available (S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid 
(L-DOPA) and triethylamine in DMF to generate compound 10.  Compound 11 was successfully 
synthesized by amidation of compound 10 with KCN-1 amine 12d in the presence of coupling 
agents EDCI and hydroxybenzotriazole (HOBt).  The final protected compound 11 was purified 
by HPLC.   
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2.2 Synthesis of KCN-1 amine 12d 
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Scheme 2.  Synthetic route of compound 12d (KCN-1 amine). 
 
The KCN-1 amine 12d was synthesized as shown in Scheme 2.  The KCN-1 12a was 
made available by the Van Meir Laboratory at Emory University.  The methoxy on the para-
position was selectively demethylated with thiophenol and K2CO3 base in N-Methyl-2-
pyrrolidone (NMP) at temperature of 150 ºC.  The time was extremely important because if the 
reaction ran more than five minutes, the methoxy on the meta-position would be demethylated 
also.  Then the hydroxyl compound 12b was alkylated with N-(4-bromobutyl) phthalimide and 
K2CO3 base in dimethylformamide (DMF).  The phthalimide KCN-1 12c was reduced to the 
final KCN-1 amine 12d by refluxing with hydrazine in a mixture of ethanol and 
dichloromethane. 
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2.3 Approaches to Compound 13 
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Scheme 3.  Synthetic routes of final deprotected compound 13. 
 
Although compound 11 was successfully synthesized, there were many complications for 
the deprotection of MOM- and Boc- groups, as shown in Scheme 3.  The molecule was very 
fragile to harsh conditions.  The trifluoroacetic acid (TFA), pKa of ~0.3, was first used to remove 
the MOM- and Boc- groups, which was unsuccessful.  At 10% TFA in DCM, only the Boc-
group was cleaved and MOM-group was intact.  At 50% TFA in DCM, the products were too 
complicated to separate and the residue, left after the reaction, had overlapping peaks on the 
HPLC.  Apparently, TFA was not a good reagent for the removal of the MOM- and Boc- groups.  
Thus, other methods were considered.  
It was reported that trace amount of concentrated HCl in MeOH at 62 ºC for 15 minutes 
can cleave the MOM-group13.  There was also an experiment that reported 4 M HCl in MeOH at 
room temperature for 30 minutes can cleave the Boc-group14.  In addition, water in the 
14 
concentrated HCl has been used to prevent double bond isomerization that occur under 
anhydrous acidic condition15.  Therefore, the second route was to use a trace concentrated HCl in 
MeOH at 60 ºC for 15 minutes.  Unfortunately, this experiment was not successful either.  
KCN-1 was found to be sensitive in acidic environment and decomposed easily based on 1H 
NMR. 
Scheme 4.  Test model reactions of boron trihalides in DCM under -100 ºC. 
 
Since HCl was too acidic for compound 11, the search for better reagents led to boron 
trihalides.  Some boron trihalides, such as boron trichloride (BCl3), boron tribromide (BBr3), and 
boron trifluoride (BF3) were considered to be good candidates.  Test model reactions were 
conducted to determine the effectiveness of the boron trihalides.  These tests consisted of one 
equivalent of KCN-1, one equivalent of photocleavable linker derivative ester, and two 
equivalents of the boron trihalides in DCM under -100 ºC, as shown in Scheme 4.  The products 
were the deprotected ester linker (P1) and the decomposed KCN-1 (P2).  The R in P2 meant that 
portion of KCN-1 had decomposed.  After the reaction was completed, the product was separated 
by flash chromatography and analyzed by 1H NMR. 
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Figure 2.1:  Test model reactions monitored by TLC. 
 
Thin layer chromatography (TLC) was used to monitor the overall reaction as shown in 
Figure 2.1.  For boron trichloride, the ester linker was deprotected completely within 30 minutes 
and KCN-1 decomposed slightly.   However, for boron tribromide, the ester linker was not fully 
deprotected and KCN-1 decomposed entirely at 15 minutes.  Boron trifluoride was even worse 
than BBr3.  For BF3, KCN-1 had decomposed at 10 minutes.  Based on these results, BCl3 was a 
better candidate because BF3 and BBr3 are too acidic for the reaction.  A milligram test of 
compound 11 will be used to determine the reactivity of BCl3 soon.  Hopefully, the deprotection 
of compound 11 will be resolved as expected. 
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3. CONCLUSION 
Compound 11 was synthesized in 10 steps with 3.6% overall yield for now, but the step 
of deprotection seems more difficult than expected.  Searching for an effective deprotecting 
reagent for compound 11 is underway now.  If an effective reagent cannot be found in the near 
future, the design of the research has to be modified to replace the MOM- group with a different 
protecting group.  Hopefully, the deprotection of compound 11 will be resolved soon.  Then this 
research will be complete once compound 11 is deprotected and attached to the immobilized 
bead.  After the small molecule is completely synthesized, it will be sent off for affinity labeling 
and analysis of the mass of the peptide sequence to determine the binding target of KCN-1. 
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4. EXPERIMENTAL 
4.1 General Methods 
NMR spectra were recorded at 400 MHz for 1H and 100 MHz for 13C on a Bruker 400 
Avance instrument.  Chemical shifts (δ values) and coupling constants (J values) are reported in 
parts per million (ppm) and hertz (Hz), respectively, using TMS (1H NMR) or deuterated solvent 
(13C NMR) as the internal standard (s = singlet, d =doublet, dd = double doublet, t = triplet, q = 
quartet, m = multiplet, br = broad).  Unless otherwise noted, all reagents and the authentic 
samples were purchased from commercial sources and were used without further purification.  
Flash chromatography was carried out on flash silica gel (Sorbent 230–400 mesh).  TLC analysis 
was conducted on silica gel plates (Sorbent Silica G UV254).  Mass spectroscopy was recorded 
on API 3200 LC/MS/MS system. 
4.2 Photocleavable Linker 
3-Hydroxy-4-iodobenzoic acid 2.  To a mixture of a solution of 3-hydroxybenzoic acid 
1 (13.8 g, 0.10 mol) in concentrated aqueous ammonia was slowly added a mixture of I2 
(23.4 g, 0.09 mol) and potassium iodide (18.6 g, 0.11 mol) in de-ionized water (100 mL) (to 
prevent from generating NI3).  The reaction mixture was stirred at room temperature for 40 
minutes, and then acidified by concentrated HCl (180 mL).  The precipitate was collected by 
filtration.  The filtrate was extracted with EtOAc (250 mL × 2).  The precipitate was combined 
with the organic layer and the EtOAc was removed under reduced pressure.  The crude 
compound was purified by recrystalization (H2O/MeOH=5/1) to yield white crystal (9.24 g, 
35%).  1H NMR (MeOD):  δ 7.79 (d, J=8.0 Hz, 1H), 7.46 (d, J=2.0 Hz, 1H), 7.22 (dd, J=8.0, 2.0 
Hz, 1H).  13C NMR (MeOD):  δ 169.5, 158.3, 140.6, 133.4, 123.1, 116.3, 93.4.  ESI-MS (−):  
Calcd for C7H5IO3:  263.93 m/z.  Found:  262.9 m/z [M−H]−. 
18 
 
5-(Hydroxymethyl)-2-iodophenol 3.  Under N2 atmosphere at 0 ºC, to a solution of 
3-hydroxy-4-iodobenzoic acid 2 (9.30 g, 0.04 mol) in anhydrous THF (100 mL) was slowly 
added borane in THF (70.0 mL, 0.07 mol).  The reaction mixture was stirred at room temperature 
overnight.  Then reaction mixture was quenched with 2 M Na2CO3 (10 mL).  The aqueous 
solution was extracted with Et2O (20 mL × 2).  The organic layer was dried with Na2SO4 and 
concentrated under reduced pressure.  The crude compound was purified by flash 
chromatography on silica gel (hexane/EtOAc=5/1) to yield pale yellow crystal (8.60 g, 86%).  1H 
NMR (CD3OD):  δ 7.61 (d, J=8.0 Hz, 1H), 6.86 (s, 1H), 6.59 (dd, J=8.0 Hz, 1H), 4.50 (s, 2H).  
13C NMR (CD3OD):  δ 158.2, 145.0, 140.3, 120.9, 114.4, 82.9, 64.6.  ESI-MS (−):  Calcd for 
C7H7IO2:  249.95 m/z.  Found:  248.4 m/z [M−H]−. 
(4-Iodo-3-(methoxymethoxy)phenyl)methanol 4.  To a mixture of 5-(hydroxymethyl)-
2-iodophenol 3 (5.00 g, 0.02 mol) and K2CO3 (5.60 g, 0.04 mol) in acetone (4 mL) was added 
methoxymethyl chloride (4 mL, 0.53 mol) and the resulting mixture was stirred at room 
temperature overnight.  The reaction mixture was filtered and washed with acetone.  The filtrate 
was concentrated under reduced pressure.  The residue was added H2O (20 mL) and EtOAc 
(20 mL).  Then the aqueous solution was further extracted with EtOAc (20 mL × 2).  The organic 
layer was dried with Na2SO4 and concentrated under reduced pressure.  The crude was purified 
by flash chromatography on silica gel (hexane/EtOAc=7/1 (200 mL), 2/1 (400 mL), 3/2 (200 
mL)) to yield yellow liquid (1.94 g, yield 33%).  ESI-MS (−):  Calcd for C9H11IO3:  293.98 m/z.  
Found:  292.9 m/z [M−H]−. 
4-(Azidomethyl)-1-iodo-2-(methoxymethoxy)benzene 5.  Under N2 atmosphere at 0 ºC, 
to a solution of (4-iodo-3-(methoxymethoxy)phenyl) methanol 4 (104 mg, 0.35 mmol) in 
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anhydrous THF (5 mL) was added diphenyl phosphorazidate (DPPA) (91 µL, 0.42 mmol) and 
the resulting mixture was stirred for ten minutes.  Then diazabicycloundecene (DBU) (64 µL, 
0.42 mmol) was added into the solution.  The reaction was warmed to room temperature and 
stirred overnight under N2.  Then reaction mixture was concentrated under reduced pressure.  
The residue was added H2O (10 mL) and EtOAc (10 mL).  The aqueous solution was further 
extracted with EtOAc (10 mL × 2).  The organic layer was dried with Na2SO4 and concentrated 
under reduced pressure.  The crude was purified by flash chromatography on silica gel 
(hexane/EtOAc=20/1) to yield yellow liquid (78 mg, yield 70%).  1H NMR (CDCl3):  δ 7.74 (d, 
J=8.0 Hz, 1H), 7.01 (d, J=2.0 Hz, 1H), 6.71 (dd, J=8.0, 2.0 Hz, 1H), 5.23 (s, 2H), 4.27 (s, 2H), 
3.49 (s, 3H).  13C NMR (CDCl3):  δ 156.3, 139.7, 137.3, 123.2, 114.4, 94.9, 86.8, 56.5, 54.2.  
ESI-MS (−):  Calcd for C9H10IN3O2:  318.98 m/z.  Found:  317.7 m/z [M−H]−. 
(4-Iodo-3-(methoxymethoxy)phenyl)methanamine 6.  To a solution of 4-
(azidomethyl)-1-iodo-2-(methoxymethoxy)benzene 5 (1.60 g, 4.9 mmol) and triphenylphosphine 
(PPh3) (2.60 g, 9.9 mmol) in THF (49 mL, 10 mL per mmol) was added de-ionized water (2 mL, 
0.04 mL per mmol) and the reaction was stirred at room temperature overnight.  The reaction 
mixture was concentrated under reduced pressure.  The residue was added brine (10 mL) and 
EtOAc (10 mL).  The aqueous solution was further extracted with EtOAc (15 mL × 2).   The 
organic layer was dried with Na2SO4 and concentrated under reduced pressure.  The crude was 
purified by flash chromatography on silica gel (hexane/EtOAc=20/1 (200 mL) to elute out PPh3, 
then pure EtOAc (100 mL) once the triphenylphosphine oxide came out, finally pure MeOH 
(300 mL) for the product) to yield yellow liquid (1.35 g, yield 94%).  ESI-MS (+):  Calcd for 
C9H12INO2:  292.99 m/z.  Found:  293.9 m/z [M+H]+. 
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tert-Butyl 4-iodo-3-(methoxymethoxy)benzylcarbamate 7.  To a solution of (4-iodo-3-
(methoxymethoxy)phenyl)methanamine 6 (25 mg, 0.08 mmol) and di-tert-butyl dicarbonate (23 
mg, 0.10 mmol) in MeOH (5 mL) was added triethylamine (14 µL, 0.10 mmol) and the resulting 
mixture was stirred at room temperature overnight.  The reaction mixture was concentrated under 
reduced pressure.  The crude was purified by flash chromatography on silica gel 
(hexane/EtOAc=10/1) to yield yellowish white crystal (17 mg, yield 53%).  1H NMR (D2O):  δ 
7.71 (d, J=8.0 Hz, 1H), 6.98 (d, J=2.0 Hz, 1H), 6.71 (d, J=8.0 Hz, 1H), 5.23 (s, 2H), 4.89 (s, 1H), 
4.25 (d, J=8 Hz, 2H), 3.51 (s, 3H), 1.46 (s, 9H).  13C NMR (D2O):  δ 156.4, 156.1, 141.4, 139.7, 
122.8, 114.1, 95.2, 85.7, 79.9, 56.7, 44.5, 28.6, 27.6.  ESI-MS (+):  Calcd for C14H20INO4:  
393.04 m/z.  Found:  394.4 m/z [M+H]+. 
(E)-3-(4-((tert-Butoxy carbonylamino) methyl)-2- (methoxymethoxy) phenyl) acrylic 
acid 8.  Under N2 atmosphere at room temperature, to a mixture of (t-Bu)4N+ Br  (188 mg, 
0.58 mmol), Pd(OAc)2 (5.4 mg, 0.02 mmol), and K2CO3 (642 mg, 4.7 mmol) was added a 
solution of tert-butyl 4-iodo-3-(methoxymethoxy)benzylcarbamate 7 (183 mg, 0.47 mmol)  in 
DMF (2 mL).  Then acrylic acid (48 µL, 0.70 mmol) was added into the mixture.  The reaction 
mixture was heated to 60o C and stirred overnight.  Then the reaction mixture was cooled to 
room temperature.  Cold H2O (5 mL) and 1 M HCl (1 mL) were added to the mixture.  The 
reaction mixture was added brine (10 mL) and EtOAc (15 mL).  The aqueous solution was 
further extracted with EtOAc (15 mL × 2).   The organic layer was dried with MgSO4 and 
concentrated under reduced pressure.  The crude was purified by flash chromatography on silica 
gel (hexane/EtOAc=20/1 (200 mL), 4/1 (400 mL), 1/1 (200 mL)) to yield yellow crystal (81 mg, 
51%).  1H NMR (D2O):  δ 8.09 (d, J=16.0 Hz, 1H), 7.51 (d, J=8.0 Hz, 1H), 7.08 (s, 1H), 6.95 (d, 
J=8.0 Hz, 1H), 6.51 (d, J=16 Hz, 1H), 5.26 (s, 2H), 4.96 (s, 1H), 4.31 (d, J=8 Hz, 2H), 3.51 (s, 
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3H), 1.47 (s, 9H).  13C NMR (D2O):  δ 172.5, 156.6, 156.2, 143.8, 141.9, 129.2, 123.0, 120.9, 
117.9, 113.8, 94.8, 80.0, 56.6, 44.7, 28.6.  ESI-MS (−):  Calcd for C17H23NO6:  337.15 m/z.  
Found:  336.2 m/z [M−H]−. 
(E)-2,5-Dioxopyrrolidin-1-yl 3-(4-((tert-butoxycarbonylamino)methyl)-2-(methoxy 
methoxy) phenyl)acrylate 9.  Under N2 atmosphere at room temperature, to a solution of (E)-3-
(4-((tert-butoxycarbonylamino)methyl)-2-(methoxymethoxy)phenyl)acrylic acid 8 (70 mg, 
0.21 mmol) and EDCI (39 mg, 0.21 mmol) in anhydrous DCM (3 mL) was added 
N-hydroxysuccinimide (24 mg, 0.21 mmol) dissolved in anhydrous DCM (1 mL) and the 
resulting mixture was stirred overnight.  The reaction mixture was concentrated under reduced 
pressure.  The residue was added brine (10 mL) and EtOAc (10 mL).  The aqueous solution was 
further extracted with EtOAc (10 mL × 2).   The organic layer was dried in MgSO4 and 
concentrated under reduced pressure.  The crude was purified by flash chromatography on silica 
gel (hexane/EtOAc=4/1 (100 mL), 3/1 (400 mL), and 1/1 (300 mL)) to yield colorless crystals 
(57 mg, 63%).  ESI-MS (+):  Calcd for C21H26N2O8:  434.17 m/z.  Found:  435.1 m/z [M+H]+. 
(E)-2-(3-(4-((tert-Butoxycarbonylamino)methyl)-2-(methoxymethoxy) phenyl) acryl 
amido ) -3-(3,4-dihydroxyphenyl)propanoic acid 10.  To a solution of (E)-2,5-dioxopyrrolidin-
1-yl 3-(4-((tert-butoxycarbonylamino)methyl)-2-(methoxymethoxy)phenyl) acrylate 9 (57 mg, 
0.13 mmol) and (S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid (L-DOPA) (22 mg, 0.11 
mmol) in anhydrous DMF (1.5 mL) was added triethyl amine (NEt3) (18 µL, 0.13 mmol) and the 
reaction was stirred at room temperature overnight.  Then the pH was adjusted from 8 to 3 by 
adding 1 M HCl (~10 mL) to the mixture.  The reaction mixture was added brine (10 mL) and 
EtOAc (15 mL). The aqueous solution was further extracted with EtOAc (10 mL × 2).  The 
organic layer was dried in MgSO4 and concentrated under reduced pressure.  The crude was 
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purified by flash chromatography on silica gel (DCM/MeOH=14/1 (200 mL), 10/1 (400 mL), 
and 5/1 (100 mL)) to yield yellow crystals (46 mg, 68%).  1H NMR (MeOD):  δ 7.82 (d, J=16 
Hz, 1H), 7.47 (d, J=8 Hz, 1H), 7.07 (s, 1H), 6.89 (d, J=8 Hz, 1H), 6.70 (d, J=16 Hz, 1H), 6.67 (s, 
1H), 6.66 (d, J=8 Hz, 1H), 6.57 (d, J=8 Hz, 1H), 5.22 (s, 2H), 4.71 (dd, J=7.2, 5.6 Hz, 1H), 4.19 
(s, 2H), 3.43 (s, 3H), 3.10 (dd, J=14, 6 Hz, 1H), 2.91 (dd, J=14, 6 Hz, 1H), 1.45 (s, 9H).  13C 
NMR (MeOD):  δ 175.9, 168.8, 158.7, 157.3, 146.2, 145.2, 144.6, 137.0, 130.1, 129.3, 124.4, 
121.9, 121.8, 121.6, 117.5, 116.4, 114.6, 95.8, 80.4, 56.9, 56.1, 44.9, 38.2, 28.9.  Calcd for 
C26H32N2O9:  516.21 m/z.  Found:  515.1 m/z [M−H]−. 
(E)-tert-Butyl 4-(3-(3-(3,4-dihydroxyphenyl)-1-(4-(4-(N-((2,2-dimethyl-2H-chromen-
6-yl)methyl)-N-phenylsulfamoyl)-2-methoxyphenoxy)butylamino)-1-oxopropan-2-
ylamino)-3-oxoprop-1-enyl)-3-(methoxymethoxy)benzylcarbamate 11.  Under N2 atmosphere 
at room temperature, to a solution of (E)-2-(3-(4-((tert-butoxycarbonylamino) methyl)-2-
(methoxy methoxy)phenyl) acrylamido)-3-(3,4-dihydroxy phenyl) propanoic acid 10 (21 mg, 
0.04 mmol), EDCI hydrochloride (8, 0.04 mmol), and HOBt (5 mg, 0.04 mmol) in anhydrous 
DCM (2 mL) was added KCN-1 amine 12d (20 mg, 0.04 mmol) dissolved in anhydrous DCM 
(0.2 mL) by a syringe.  Two equivalent of anhydrous DCM (0.2 mL) was used to wash the vial 
and syringe used to add the KCN-1 amine.  The reaction was stirred at room temperature 
overnight.  The reaction mixture was concentrated under reduced pressure.  The crude was 
purified by flash chromatography on silica gel (DCM/MeOH=20/1 (100 mL), 10/1 (100 mL), 5/1 
(150 mL), pure MeOH (50 mL)) to yield white crystal (19 mg, 47%).  1H NMR (MeOD):  δ 7.85 
(d, J=16 Hz, 1H), 7.51 (d, J=8 Hz, 1H), 7.29 (m, 2H), 7.23 (m, 3H), 7.08 (m, 3H), 7.00 (m, 2H), 
6.93 (m, 2H), 6.82 (m, 1H), 6.69 (m, 2H), 6.60 (m, 1H), 6.53 (m, 1H), 6.22 (d, J=10 Hz, 1H), 
5.62 (d, J=10 Hz, 1H), 5.25 (s, 3H), 4.61 (s, 3H), 4.21 (s, 2H), 4.02 (t, 2H), 3.69 (s, 3H), 3.44 (s, 
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3H), 3.14 (dd, J=12, 6 Hz, 1H), 2.96 (dd, J=12, 6 Hz, 1H), 2.86 (dd, J=12, 6 Hz, 1H), 1.65 (m, 
5H).  13C NMR (MeOD):  δ 173.7, 168.8, 157.5, 153.9, 150.6, 146.4, 145.4, 140.6, 137.3, 132.2, 
131.1, 130.6, 129.9, 129.1, 127.9, 124.5, 123.2, 122.6, 121.75, 117.6, 117.1, 116.6, 114.7, 113.2, 
111.9, 95.9, 80.5, 77.5, 70.0, 57.1, 56.7, 55.1, 49.8, 48.5, 45.0, 40.0, 38.9, 30.9, 28.9, 28.3, 27.3, 
27.0.  ESI-MS (−):  Calcd for C55H64N4O13S:  1020.42 m/z.  Found:  1019.8 m/z [M−H]−. 
4.3 KCN-1 AMINE (12d) 
N-((2,2-Dimethyl-2H-chromen-6-yl)methyl)-4-hydroxy-3-methoxy-N-phenyl 
benzene sulfonamide 12b.  Under N2 atmosphere at 150 ºC, to a mixture of K2CO3 (149 mg, 
1.07 mmol) in N-Methyl-2-pyrrolidone (NMP) (2 mL) was added thiophenol (PhSH) (0.11 mL, 
1.07 mmol) and the reaction mixture was stirred for 15 minutes.  Then a solution of N-((2,2-
dimethyl-2H-chromen-6-yl)methyl)-3,4-dimethoxy-N-phenylbenzene-sulfonamide 12a (100 mg, 
0.21 mmol) in NMP (1 mL) was added into the reaction mixture.  The reaction was stirred for 5 
minutes (no longer than 5 minutes) and immediately poured into cold de-ionized H2O (25 mL).  
The aqueous solution was extracted with EtOAc (50 mL × 4).  Brine (~10 mL) was added as 
needed for better separation.  The organic layer was washed with de-ionized water (20 mL × 6) 
to get rid of most of NMP.  The organic layer was dried in MgSO4 and concentrated under 
reduced pressure.  The crude was purified by flash chromatography on silica gel 
(DCM/EtOAc=50/1 (500 mL), 30/1 (200 mL)) to yield white crystal (57 mg, 60%).  ESI-MS (−):  
Calcd for C25H25NO5S:  451.15 m/z.  Found:  450.1 m/z [M−H]−. 
N-((2,2-Dimethyl-2H-chromen-6-yl)methyl)-4-(4-(1,3-dioxoisoindolin-2-yl)butoxy)-3-
methoxy-N-phenylbenzenesulfonamide 12c.  Under N2 atmosphere at 50 º C, a solution of 2-
(4-bromobutyl) isoindoline-1,3-dione (90 mg, 0.32 mmol), N-((2,2-dimethyl-2H-chromen-6-
yl)methyl)-4-hydroxy-3-methoxy-N-phenyl benzenesulfonamide 12b (130 mg, 0.29 mmol), and 
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K2CO3 (44 mg, 0.32 mmol) in (DMF) (2 mL) was stirred overnight.  The reaction mixture was 
added de-ionized H2O (20 mL) and EtOAc (20 mL).  The aqueous solution was further extracted 
with EtOAc (100 mL × 2).  The organic layer was dried in MgSO4 and concentrated under 
reduced pressure.  The crude was purified by flash chromatography on silica gel 
(DCM/EtOAc=50/1) to yield colorless solid (89 mg, 47%).  1H NMR (MeOD):  δ 7.75 (m, 2H), 
7.65 (m, 2H), 7.32 (m, 1H), 7.27 (m, 3H), 6.99 (m, 2H), 6.97 (m, 4H), 6.59 (d, J=8 Hz, 1H), 6.21 
(d, J=8 Hz, 1 H), 5.55 (d, J=8 Hz, 1H), 4.59 (s, 2H), 4.12 (m, 3H), 3.88 (m, 2H), 3.73 (s, 3H), 
2.04 (s, 1H), 1.92 (s, 4H), 1.27 (s, 6H), 1.24 (m, 2H).  ESI-MS (+):  Calcd for C37H36N2O7S:  
652.22 m/z.  Found:  653.3 m/z [M+H]+. 
4-(4-Aminobutoxy)-N-((2,2-dimethyl-2H-chromen-6-yl)methyl)-3-methoxy-N-phenyl 
benzenesulfonamide (KCN-1 amine) 12d.  Under N2 atmosphere at refluxed, to a solution of 
N-((2,2-dimethyl-2H-chromen-6-yl)methyl)-4-(4-(1,3-dioxoisoindolin-2-yl)butoxy)-3-methoxy-
N-phenylbenzenesulfonamide 12c (48 mg, 0.07 mmol) in EtOH/DCM (75/25) (3 mL) was added 
hydrazine monohydrate (H2N-NH2·H2O) (7.1 µL, 0.15 mmol) and the resulting mixture was 
stirred overnight.  The reaction mixture was concentrated under reduced pressure and then 
vacuum filtrate with DCM.  The filtrate organic layer was concentrated under reduced pressure.  
The crude was purified by flash chromatography on silica gel (DCM/MeOH=20/1 (200 mL), 
10/1 (500 mL), 5/1 (300 mL)) to yield colorless solid (20 mg, 55%).  1H NMR (MeOD):  δ 7.29 
(m, 1H), 7.27 (m, 3H), 6.98 (m, 2H), 6.94 (m, 1H), 6.91 (m, 2H), 6.85 (m, 1H), 6.57 (d, J=8 Hz, 
1H), 6.20 (d, J=8 Hz, 1H), 5.55 (d, J=8 Hz, 1H), 4.60 (s, 2H), 4.05 (t, 2H), 3.69 (s, 3H), 2.74 (t, 
2H), 1.87 (m, 5H), 1.70 (s, 3H), 1.61 (m, 2H), 1.35 (s, 6H).  ESI-MS (+):  Calcd for 
C29H34N2O5S:  522.22 m/z.  Found:  523.3 m/z [M+H]+. 
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